Title

Acute and subacute toxicity evaluation of mega sanjeevi chooranam in rats

Authors

S. Iyswarya^1,*, S. Sivakkumar¹, S. Visweswaran¹, Thomas Reshmee Varghese² & S. Kalpana³

Affiliation

¹Department of Gunapadam, National Institute of Siddha (Affiliated with Dr. M.G.R. Medical University), Tambaram Sanatorium, Chennai, 600047, Tamil Nadu, India; ²Department of Pharmacology, National Institute of Siddha (Affiliated with Dr. MGR Medical University), Tambaram Sanatorium, Chennai, 600047, Tamil Nadu, India; ³Department of Epidemiology, The TN. Dr. MGR Medical University, Guindy, Chennai-600032, Tamil Nadu, India; *Corresponding author

Email

S. Iyswarya - E-mail: iysbsms@gmail.com

S. Sivakkumar - E-mail: s.sivakkumar.nis@gov.in

S. Visweswaran - E-mail: s.visweswaran.nis@gov.in

Thomas Reshmee Varghese- E-mail: drreshmee1@gmail.com

S. Kalpana - E-mail: kalpana.s@tnmgrmu.ac.in

Article Type

Research Article

Date

Received July 1, 2026; Revised July 31, 2026; Accepted July 31, 2026, Published July 31, 2026

Abstract

Mega Sanjeevi Chooranam (MSC), a Siddha formulation indicated for Madhumegam (Diabetes mellitus), lacks validated safety data. Therefore, it is of interest to evaluate its preclinical safety in Wistar rats using acute and 28-day repeated oral toxicity models in accordance with OECD guidelines 423 and 407. MSC caused no mortality or treatment-related toxic effects up to 2000 mg/kg (acute) and 1800 mg/kg/day (subacute), with no significant alterations in clinical, hematological, biochemical, or histopathological parameters, confirming a favorable safety profile for further clinical evaluation.

Keywords

Mega Sanjeevi Chooranam; siddha medicine; OECD guidelines; madhumegam; diabetes mellitus (DM)

Citation

Iyswarya et al. Bioinformation 22(7): 4438-4444 (2026)

Edited by

P Kangueane

ISSN

0973-2063

Publisher

Biomedical Informatics

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.